+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Circulating Tumor Cells (CTC) Market (2021-2026) by Technology, Application, Product, Specimen, End-User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 169 Pages
  • November 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5515420
The Global Circulating Tumor Cells (CTC) Market is estimated to be USD 9.52 Bn in 2021 and is expected to reach USD 18.41 Bn by 2026, growing at a CAGR of 14.1%.

Market Dynamics

Key factors such as the growing incidence of cancer followed by the increasing potential of CTCs in diagnosis and treatment have been a prominent driver for the Global Circulating Tumor Cells (CTC) Market. Similarly, the shifting preference towards minimally invasive diagnostic methods and higher awareness about cancer has led to preventive initiatives taken by individuals in demand for preventive medicines.

However, factors such as lack of awareness and technical difficulties in detection are likely to restrain the market growth. Moreover, stringent government regulations and reluctance to adopt novel CTC technologies are posing to cause significant challenges for the market growth.

Market Segmentation

The Global Circulating Tumor Cells (CTC) Market is segmented further based on Technology, Application, Product, Specimen, End-User, and Geography.

By Technology, the market is classified as CTC Enrichment, CTC Detection, and CTC Analysis. Amongst all, the CTC Detection segment holds the highest market share.

By Application, the market is classified as Multiple Chromosome Abnormalities, RNA Profiling, Protein Expression, and Cellular Communication. Amongst all, the Multiple Chromosomal Abnormalities segment is estimated to hold the highest market share.

By Product, the market is classified as Devices or Systems, Kits & Reagents, and Blood Collection Tubes. Amongst all, the Devices or Systems segment accounted for the largest share in the market for CTCs.

By Specimen, the market is classified as Blood, Bone Marrow, and Other Body Fluids. Amongst all, the Blood segment holds the highest market share.

By End-user, the market is classified as Research & Academic Institutes, Hospitals & Clinics, and Diagnostic Centers. Amongst all, the Hospital & Clinics segment holds the highest market share.

By Geography, North America is projected to lead the market.

Recent Developments

1. Biocept Inc has bought its product Target Selector™ assays to the physicians for evaluating the cerebrospinal fluid (CSF) of their patients in the presence of circulating tumor cells (CTCs). 14th January 2020
2. LineaRx, a subsidiary of Applied DNA Sciences has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc., a biotech company providing innovative solutions in Invasive, Circulating Tumor Cells (iCTCs).. - 8th August 2019

Company Profiles

Some of the companies covered in this report are Aviva Biosciences, Advanced Cell Diagnostics, Biocept, LungLife AI, Creatv Micro Tech, Miltenyi Biotec, Menarini Silicon Biosystems, Precision for Medicine, Qiagen, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Circulating Tumor Cells (CTC) Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Circulating Tumor Cells (CTC) Market

What is the estimated value of the Global Circulating Tumor Cells (CTC) Market?

The Global Circulating Tumor Cells (CTC) Market was estimated to be valued at $9520 Million in 2021.

What is the growth rate of the Global Circulating Tumor Cells (CTC) Market?

The growth rate of the Global Circulating Tumor Cells (CTC) Market is 14.1%, with an estimated value of $18410 Million by 2026.

What is the forecasted size of the Global Circulating Tumor Cells (CTC) Market?

The Global Circulating Tumor Cells (CTC) Market is estimated to be worth $18410 Million by 2026.

Who are the key companies in the Global Circulating Tumor Cells (CTC) Market?

Key companies in the Global Circulating Tumor Cells (CTC) Market include ApoCell (Precision for Medicine), Bio, Techne, Biocept, Greiner Bio One International, Biofluidica Microtechnologies, Celltraffix, Clearbridge Biomedics and Cynvenio Biosystems.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Growing Incidence of Cancer and Potential Of CTC In Diagnosis and Treatment
4.1.2 Increasing Demand for Preventive Medicine and Companion Diagnostics
4.1.3 Increasing Preference for Non-Invasive Methods Cancer Diagnosis
4.2 Restraints
4.2.1 Stringent Government Regulations
4.2.2 Technical Difficulties in Detection
4.2.3 High Variability Among Patient Samples and Assays in Immuno-Oncology Trials
4.3 Opportunities
4.3.1 Increasing R&D Activities in CTC Analysis and Detection Practices
4.3.2 Advancements in Chip Technology
4.3.3 Emergence of New Single-Cell Technologies
4.4 Challenges
4.4.1 Lack Of Awareness
4.4.2 Reluctance For the Adoption of Novel CTC Technologies
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Circulating Tumor Cells (CTC) Market, By Technology
6.1 Introduction
6.2 CTC Enrichment
6.2.1 Immunocapture/Label-Based Positive Selection Negative Selection
6.2.2 Size-Based Separation/Label-Free Membrane-Based Size Separation (Label-Free) Microfluidic-Based Size Separation (Label-Free)
6.2.3 Density-Based Separation (Label-Free)
6.2.4 Combined Methods (Label-Free)
6.3 CTC Direct Detection
6.3.1 Microscopy
6.3.2 SERS
6.3.3 Immunocytochemical Technology
6.3.4 Molecular (RNA)-Based Technology
6.3.5 Others
6.4 CTC Analysis & Downstream Assays
7 Global Circulating Tumor Cells (CTC) Market, By Application
7.1 Introduction
7.2 Multiple Chromosome Abnormalities
7.3 RNA Profiling
7.4 Protein Expression
7.5 Cellular Communication
8 Global Circulating Tumor Cells (CTC) Market, By Product
8.1 Introduction
8.2 Devices or Systems
8.3 Kits & Reagents
8.4 Blood Collection Tubes
9 Global Circulating Tumor Cells (CTC) Market, By Specimen
9.1 Introduction
9.2 Blood
9.3 Bone Marrow
9.4 Other Body Fluids
10 Global Circulating Tumor Cells (CTC) Market, By End User
10.1 Introduction
10.2 Research & Academic Institutes
10.3 Hospitals/ Clinics
10.4 Diagnostic Centers
11 Global Circulating Tumor Cells (CTC) Market, By Geography
11.1 Introduction
11.2 America
11.2.1 Argentina
11.2.2 Brazil
11.2.3 Canada
11.2.4 Chile
11.2.5 Colombia
11.2.6 Mexico
11.2.7 Peru
11.2.8 United States
11.2.9 Rest of Americas
11.3 Europe
11.3.1 Austria
11.3.2 Belgium
11.3.3 Denmark
11.3.4 Finland
11.3.5 France
11.3.6 Germany
11.3.7 Italy
11.3.8 Netherlands
11.3.9 Norway
11.3.10 Poland
11.3.11 Russia
11.3.12 Spain
11.3.13 Sweden
11.3.14 Switzerland
11.3.15 United Kingdom
11.3.16 Rest of Europe
11.4 Middle East and Africa
11.4.1 Egypt
11.4.2 Israel
11.4.3 Qatar
11.4.4 Saudi Arabia
11.4.5 South Africa
11.4.6 United Arab Emirates
11.4.7 Rest of MEA
11.5 Asia-Pacific
11.5.1 Australia
11.5.2 Bangladesh
11.5.3 China
11.5.4 India
11.5.5 Indonesia
11.5.6 Japan
11.5.7 Malaysia
11.5.8 Philippines
11.5.9 Singapore
11.5.10 South Korea
11.5.11 Sri Lanka
11.5.12 Thailand
11.5.13 Taiwan
11.5.14 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements
13 Company Profiles
13.1 ApoCell (Precision for Medicine)
13.2 Bio-Techne
13.3 Biocept
13.4 Greiner Bio One International
13.5 Biofluidica Microtechnologies
13.6 Celltraffix
13.7 Clearbridge Biomedics
13.8 Creatv Microtech
13.9 Cynvenio Biosystems
13.10 Fluxion Biosciences
13.11 Ikonisys
13.12 Janssen Diagnostics
13.13 Qiagen
13.14 Rarecells
13.15 Screencell
13.16 Stemcell Technologies (NeoStem)
13.17 Canopus Bioscience
13.18 Cellmax Life
13.19 Synergex
13.20 Sysmex
13.21 Vitatex
13.22 Aviva Biosciences
13.23 Advanced Cell Diagnostics
13.24 LungLife AI
13.25 Miltenyi Biotec
13.26 Menarini Silicon Biosystem
14 Appendix
14.1 Questionnaire

Companies Mentioned

  • ApoCell (Precision for Medicine)
  • Bio-Techne
  • Biocept
  • Greiner Bio One International
  • Biofluidica Microtechnologies
  • Celltraffix
  • Clearbridge Biomedics
  • Creatv Microtech
  • Cynvenio Biosystems
  • Fluxion Biosciences
  • Ikonisys
  • Janssen Diagnostics
  • Qiagen
  • Rarecells
  • Screencell
  • Stemcell Technologies (NeoStem)
  • Canopus Bioscience
  • Cellmax Life
  • Synergex
  • Sysmex
  • Vitatex
  • Aviva Biosciences
  • Advanced Cell Diagnostics
  • LungLife AI
  • Miltenyi Biotec
  • Menarini Silicon Biosystem